[go: up one dir, main page]

PT3068796T - Miméticas de calcitonina para tratar doenças e distúrbios - Google Patents

Miméticas de calcitonina para tratar doenças e distúrbios

Info

Publication number
PT3068796T
PT3068796T PT148023450T PT14802345T PT3068796T PT 3068796 T PT3068796 T PT 3068796T PT 148023450 T PT148023450 T PT 148023450T PT 14802345 T PT14802345 T PT 14802345T PT 3068796 T PT3068796 T PT 3068796T
Authority
PT
Portugal
Prior art keywords
disorders
treating diseases
calcitonin mimetics
calcitonin
mimetics
Prior art date
Application number
PT148023450T
Other languages
English (en)
Inventor
Karsdal Morten
Henriksen Kim
Vietz Andreassen Kim
Original Assignee
Keybioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201320112A external-priority patent/GB201320112D0/en
Priority claimed from GB201414706A external-priority patent/GB201414706D0/en
Application filed by Keybioscience Ag filed Critical Keybioscience Ag
Publication of PT3068796T publication Critical patent/PT3068796T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT148023450T 2013-11-14 2014-11-10 Miméticas de calcitonina para tratar doenças e distúrbios PT3068796T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201320112A GB201320112D0 (en) 2013-11-14 2013-11-14 Calcitonin Mimetics for treating diseases and disorders
GB201414706A GB201414706D0 (en) 2014-08-19 2014-08-19 Calcitonin mimetics for treating diseases and disorders

Publications (1)

Publication Number Publication Date
PT3068796T true PT3068796T (pt) 2018-03-02

Family

ID=51947308

Family Applications (2)

Application Number Title Priority Date Filing Date
PT17208140T PT3321278T (pt) 2013-11-14 2014-11-10 Miméticas de calcitonina para tratar doenças e distúrbios
PT148023450T PT3068796T (pt) 2013-11-14 2014-11-10 Miméticas de calcitonina para tratar doenças e distúrbios

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT17208140T PT3321278T (pt) 2013-11-14 2014-11-10 Miméticas de calcitonina para tratar doenças e distúrbios

Country Status (24)

Country Link
US (2) US10232021B2 (pt)
EP (3) EP3470422A1 (pt)
JP (1) JP6639389B2 (pt)
KR (1) KR20160075794A (pt)
CN (1) CN105722854B (pt)
AU (2) AU2014350328B2 (pt)
BR (1) BR112016010643A2 (pt)
CA (1) CA2928654A1 (pt)
CY (2) CY1119976T1 (pt)
DK (2) DK3068796T3 (pt)
ES (2) ES2660788T3 (pt)
HR (2) HRP20180337T1 (pt)
HU (2) HUE044465T2 (pt)
LT (2) LT3321278T (pt)
MX (1) MX373251B (pt)
NO (1) NO3068796T3 (pt)
PH (1) PH12016500705B1 (pt)
PL (2) PL3068796T3 (pt)
PT (2) PT3321278T (pt)
RS (2) RS58530B1 (pt)
RU (1) RU2689551C1 (pt)
SI (2) SI3321278T1 (pt)
TR (1) TR201802765T4 (pt)
WO (1) WO2015071229A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
KR101869595B1 (ko) 2016-06-08 2018-06-21 부경대학교 산학협력단 성게 유래 칼시토닌 유사 펩타이드를 유효성분으로 포함하는 골 질환 예방 또는 치료용 조성물
CN108424460A (zh) * 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 GLP-1类似物和davalintide类似物的融合蛋白制备及其用途
CN106880835A (zh) * 2017-02-17 2017-06-23 云南同方科技有限公司 用于缓解高血压症状的植物精油复合物制备及应用
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
TWI901925B (zh) 2020-12-18 2025-10-21 美商美國禮來大藥廠 雙重澱粉素及降鈣素受體促效劑及其用途
CA3266547A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company COMPOSITIONS FOR ORAL ADMINISTRATION
WO2025240893A1 (en) 2024-05-17 2025-11-20 Eli Lilly And Company 4-phenyl-1h-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
JPH03240797A (ja) * 1990-02-15 1991-10-28 Sagami Chem Res Center 新規カルシトニン誘導体
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
JPH04149198A (ja) * 1990-10-12 1992-05-22 Sagami Chem Res Center カルシトニン誘導体
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE69841939D1 (de) 1997-04-16 2010-11-25 Unigene Lab Inc Direkte expression von peptiden ins kulturmedium
DE19736457C2 (de) * 1997-08-21 2001-08-23 Fraunhofer Ges Forschung Calcitonin-Derivate mit einer Verbrückung zwischen den Aminosäuren an den Positionen 17 und 21
WO2000033866A1 (en) 1998-12-04 2000-06-15 Provalis Uk Limited Pharmaceutical compositions containing insulin
JP4588221B2 (ja) 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1608347B1 (en) 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
AU2004262906B2 (en) 2003-07-23 2008-04-03 Nordic Bioscience A/S Use of calcitonin in osteoarthritis
JP2007523050A (ja) 2003-09-17 2007-08-16 カイアズマ・リミテッド 生物学的障壁を通した透過を容易にすることのできる組成物
JP2008506750A (ja) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー チオール基を含む化合物の排出ポンプ抑制剤としての使用
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
DK1907561T3 (da) 2005-06-24 2013-12-02 Enteris Biopharma Inc Cellelinjer til ekspression af enzym, der er anvendeligt i fremstillingen af amiderede produkter
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PT1834635E (pt) 2006-03-13 2011-10-13 Advanced In Vitro Cell Technologies S L Sistemas estáveis de nanocápsula para a administração de moléculas activas
RU2437662C2 (ru) 2006-04-07 2011-12-27 Меррион Рисерч Iii Лимитед Твердая пероральная лекарственная форма, содержащая усилитель
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP5833246B2 (ja) * 2011-10-25 2015-12-16 ニシラ， インコーポレイテッド ユニバーサルフローを変換するためのシャーシコントローラ
KR102019911B1 (ko) * 2011-11-02 2019-09-09 키바이오사이언스 아게 질병 및 장애 치료용 펩타이드 유사체

Also Published As

Publication number Publication date
HRP20180337T1 (hr) 2018-05-18
SI3321278T1 (sl) 2019-04-30
RS57152B1 (sr) 2018-07-31
AU2014350328A1 (en) 2016-05-19
ES2713851T3 (es) 2019-05-24
BR112016010643A2 (pt) 2017-12-05
PH12016500705A1 (en) 2016-05-30
HUE044465T2 (hu) 2019-10-28
TR201802765T4 (tr) 2018-03-21
JP6639389B2 (ja) 2020-02-05
EP3068796B1 (en) 2018-01-31
PT3321278T (pt) 2019-03-19
EP3321278B1 (en) 2019-01-09
MX2016006049A (es) 2016-08-12
PL3321278T3 (pl) 2019-06-28
LT3068796T (lt) 2018-05-10
EP3321278A1 (en) 2018-05-16
EP3068796A1 (en) 2016-09-21
AU2014350328B2 (en) 2018-04-05
KR20160075794A (ko) 2016-06-29
CY1121332T1 (el) 2020-05-29
CN105722854A (zh) 2016-06-29
JP2016538282A (ja) 2016-12-08
US20170143800A1 (en) 2017-05-25
CN105722854B (zh) 2020-08-04
PH12016500705B1 (en) 2016-05-30
CA2928654A1 (en) 2015-05-21
WO2015071229A1 (en) 2015-05-21
NO3068796T3 (pt) 2018-06-30
AU2018202480A1 (en) 2018-04-26
RU2016123180A (ru) 2017-12-19
US20190142903A1 (en) 2019-05-16
CY1119976T1 (el) 2018-12-12
EP3470422A1 (en) 2019-04-17
DK3068796T3 (en) 2018-03-05
ES2660788T3 (es) 2018-03-26
US10232021B2 (en) 2019-03-19
LT3321278T (lt) 2019-03-12
MX373251B (es) 2020-05-04
DK3321278T3 (en) 2019-03-25
HUE037663T2 (hu) 2018-09-28
RU2689551C1 (ru) 2019-05-28
HRP20190356T1 (hr) 2019-04-19
SI3068796T1 (en) 2018-05-31
RS58530B1 (sr) 2019-04-30
PL3068796T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
HRP20190356T1 (hr) Mimetici kalcitonina za liječenje bolesti i poremećaja
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
PL3046470T3 (pl) Diagnozowanie i leczenie zaburzeń ruchu
ZA201601634B (en) Composition comprising torasemide and baclofen for treating neurological disorders
IL244014A0 (en) Combined therapy for the treatment of glioblastoma
SG11201509012QA (en) Sobetirome in the treatment of myelination diseases
EP2952149A4 (en) THERAPEUTIC TREATMENT DEVICE
GB201304872D0 (en) Treatment
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
IL276431A (en) Treatment of the brain disorders and related symptoms
IL253026A0 (en) Calcitonin analogs for the treatment of diseases and disorders
PT3095484T (pt) Miméticas de calcitonina para tratar doenças e distúrbios
GB201307310D0 (en) Treatment
GB201320112D0 (en) Calcitonin Mimetics for treating diseases and disorders
GB201414706D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201313178D0 (en) Therapeutic treatments
GB201313182D0 (en) Therapeutic treatments
GB201301072D0 (en) Therapeutic Moisturiser
GB201300778D0 (en) Therapeutic moisturiser
GB201321115D0 (en) Treatment
GB201309393D0 (en) Metal treatment
GB201309238D0 (en) Treatment